Get started
Author

Antje Margret Wengner

Observed names: A M Wengner, A. Wengner, A.M. Wengner, Antje M Wengner, Antje M. Wengner, Antje Margret Wegner, Antje Wengner, Wengner, Antje M, Wengner, Antje M.
Institution: Bayer (Germany)
ORCID: 0009-0009-5772-1945
Observed ORCID: 0009-0009-5772-1945
OpenAlex ID: A5064749364
Differential Mobilization of Subsets of Progenitor Cells from the Bone Marrow
2009 · Simon C. Pitchford, Rebecca C. Furze, et al. · Cell stem cell · 278
PDF
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
2020 · Timothy A. Yap, David S.P. Tan, et al. · Cancer Discovery · 270
The coordinated action of G-CSF and ELR + CXC chemokines in neutrophil mobilization during acute inflammation
2007 · Antje M. Wengner, Simon C. Pitchford, et al. · Blood · 237
PDF
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models
2019 · Antje M. Wengner, Gerhard Siemeister, et al. · Molecular Cancer Therapeutics · 213
The Lab Oddity Prevails: Discovery of Pan‐CDK Inhibitor (R)‐S‐Cyclopropyl‐S‐(4‐{[4‐{[(1R,2R)‐2‐hydroxy‐1‐methylpropyl]oxy}‐5‐(trifluoromethyl)pyrimidin‐2‐yl]amino}phenyl)sulfoximide (BAY 1000394) for the Treatment of Cancer
2013 · Ulrich Lücking, Rolf Jautelat, et al. · ChemMedChem · 186
BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
2012 · Gerhard Siemeister, Ulrich Lücking, et al. · Molecular Cancer Therapeutics · 161
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT
2017 · Juliane Paul, Maurice Soujon, et al. · Cancer Cell · 150
CXCR5‐ and CCR7‐dependent lymphoid neogenesis in a murine model of chronic antigen‐induced arthritis
2007 · Antje M. Wengner, Uta E. Höpken, et al. · Arthritis & Rheumatism · 119
Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity
2016 · Antje M. Wengner, Gerhard Siemeister, et al. · Molecular Cancer Therapeutics · 118
Characterization of novel MPS1 inhibitors with preclinical anticancer activity
2013 · M Jemaà, L Galluzzi, et al. · Cell Death and Differentiation · 117
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models
2020 · Ulrich Lücking, Lars Wortmann, et al. · Journal of Medicinal Chemistry · 86
Adaptive peripheral immune response increases proliferation of neural precursor cells in the adult hippocampus
2009 · Susanne A. Wolf, Barbara Steiner, et al. · The FASEB Journal · 83
Targeting DNA Damage Response in Prostate and Breast Cancer
2020 · Antje M. Wengner, Arne Scholz, et al. · International Journal of Molecular Sciences · 81
PDF
BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity
2017 · Susann Santag, Franziska Siegel, et al. · Cancer Letters · 66
PDF
CCR7 deficiency causes ectopic lymphoid neogenesis and disturbed mucosal tissue integrity
2006 · Uta E. Höpken, Antje M. Wengner, et al. · Blood · 63
PDF
Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase
2020 · Volker K. Schulze, Ulrich Klar, et al. · Journal of Medicinal Chemistry · 60
Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
2019 · Katrine Wickstroem, Urs B. Hagemann, et al. · Journal of Nuclear Medicine · 53
PDF
Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor
2019 · Julien Lefranc, Volker Klaus Schulze, et al. · Journal of Medicinal Chemistry · 48
Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839
2024 · Ulrich Bothe, Judith Günther, et al. · Journal of Medicinal Chemistry · 45
PDF
A Novel NAMPT Inhibitor-Based Antibody–Drug Conjugate Payload Class for Cancer Therapy
2022 · Niels Böhnke, Markus Berger, et al. · Bioconjugate Chemistry · 39
Targeted thorium-227 conjugates as treatment options in oncology
2023 · Jenny Karlsson, Christoph A. Schatz, et al. · Frontiers in Medicine · 34
PDF
First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.
2019 · Johann S. De Bono, David Shao Peng Tan, et al. · Journal of Clinical Oncology · 31
Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing
2019 · Timothy A. Lewis, Luc de Waal, et al. · ACS Medicinal Chemistry Letters · 30
Therapeutic targeting of ATR in alveolar rhabdomyosarcoma
2022 · Heathcliff Dorado García, Fabian Pusch, et al. · Nature Communications · 29
PDF
Degradation of oxidized extracellular proteins by microglia
2002 · Alexandra Stolzing, Antje Wengner, et al. · Archives of Biochemistry and Biophysics · 28
Works count: 176
Citation count: 2,866
H-index: 26
I10-index: 34
Year
Topic
Type